Itolizumab Anti-Human CD6 Recombinant Antibody|cas:1116433-11-4|西域试剂

Itolizumab Anti-Human CD6 Recombinant Antibody

产品编号：Bellancom-P99252| CAS NO：1116433-11-4

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99252		￥4500.00	杭州北京（现货）
Bellancom-P99252		￥11700.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Itolizumab Anti-Human CD6 Recombinant Antibody

产品介绍

Itolizumab (Anti-Human CD6 Recombinant Antibody) 是一种人源化重组 抗 CD6 单克隆抗体 (MAb)，靶向 CD6 的细胞外 SRCR 远端结构域 1。Itolizumab 可减少 T 细胞增殖并抑制促炎细胞因子的产生，例如 INF-γ、TNFα 和 IL-6。Itolizumab 可用于银屑病、类风湿性关节炎 (RA)、COVID-19 的研究。

生物活性

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19.

体外研究

Itolizumab (100 μg/mL) inhibits T cell proliferation^[4].
Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances acquisition of Th1 phenotype in PBMCs^[4].
Itolizumab (40 μg/mL) reduces CD26^hiCD161+ CD8+ T cells during culture of PBMCs overnight^[5].
Itolizumab (40 μg/mL, 3-12 days) reduces the expression of IL-17 and IFN-γ in PBMCs stimulated in Th17 polarizing conditions^[6].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD)^[7].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)^[7]
Dosage:	60 μg or 300μg
Administration:	Intraperitoneal injection (i.p.), prior to PBMC transplantation.
Result:	Decreased mortality compared to the vehicle (100% vs. 10%).

体内研究

Itolizumab (60 μg or 300μg, i.p., everyday) shows therapeutic efficiency in a humanized xenograft mouse model of Graft Vs Host Disease (GVHD)^[7].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Humanized xenograft mice, generated by intravenous transfer human PBMCs into 6-8 weeks old NOD/SCID IL2rγ-null (NSG)^[7]
Dosage:	60 μg or 300μg
Administration:	Intraperitoneal injection (i.p.), prior to PBMC transplantation.
Result:	Decreased mortality compared to the vehicle (100% vs. 10%).